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Proper implementation of  efficient malaria control tools 
is essential to program success and public health. Millions 
of  lives are affected annually due to the disease, and despite 
widespread treatment and prevention efforts, malaria remains 
a scourge on the African continent1. Important strategies 
to prevent the disease involve (1) use of  vector control 
measures, such as insecticide-treated nets (ITN) or indoor 
residual spray (IRS) and (2) the development of  vaccines 
that protect humans or reduce transmission. Successful 
implementation of  these strategies can result in significant 
malaria reduction2, but this requires careful consideration of  
the communities in which these strategies are implemented. 
A deep understanding of  community perceptions and 
expectations is fundamental to crafting an effective malaria 
reduction strategy.
In his paper published in the  Malawi Medical Journal, 
Parker et al. addresses important questions regarding the 
assessment of  community perception in malaria-endemic 
areas. The authors discussed the practical limitations of  bed 
net usage based on common behaviors that perhaps were 
not considered during program design; for example, in the 
evening, many community members chat with neighbors 
outside prior to going to bed, and despite proper bed net 
usage, they can still contract malaria. This may foster the 
perception that ITNs are ineffective. Further, understanding 
community perceptions will not only identify challenges 
and limitations, but may also reveal possible improvements, 
solutions, and alternative strategies. One common perception 
is that insect repellents could be provided for routine use by 
the community, and not just by tourists. In addition, engaged 
community members are ultimately responsible for social 
mobilization, increasing public awareness, and education on 
prevention efforts. 
While several studies have evaluated community perception 
on vector control, a strategy successfully implemented in 
the field, few have analyzed the acceptability of  malaria 
vaccines, a much newer approach for malaria control and 
eradication. Many types of  malaria vaccines are currently 
under development and several are being tested in clinical 
trials[3], but some questions related to malaria vaccines 
need evaluation. Among the three countries selected for 
pilot implementation of  RTS,S vaccine, Ghana and Kenya 
have published studies assessing community perceptions 
of  malaria vaccines4,5 and studies in Malawi will be similarly 
important.
Intramuscular delivery of  malaria vaccines is generally 
well-accepted6, but the protection achieved by this route is 
relatively modest and short-lived7. In contrast, intravenous 
delivery may confer a higher level of  protection8,9 but we 
still do not know how communities view the implementation 
of  an intravenous vaccine. Several questions need to be 
addressed in future studies of  malaria vaccines: can the 
community understand, accept, and promote the idea of  
receiving a whole organism vaccine? What do people in 
endemic areas think about vaccines made with genetically 
attenuated parasites? Are they receptive to the idea of  
receiving a transmission-blocking vaccine that can protect 
the community, but not themselves directly?  Listening to the 
community can improve the strategies already implemented 
or in development. Let’s hear what they have to say.
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